To test this hypothesis, we examined the effects of CD137 activation therapies using our previously characterized mouse model of HPV (+) HNSCC, comparing the effects of systemic activation (via activating monoclonal anti-CD137 antibody treatment) versus a tumor-localized activation (via overexpression of CD137L on tumor cells). Here, TNFRSF9 is linked to neoplasm.